Key result
OAC discontinuation at 6 months post-ablation shows no benefit over continuation for major events.
Why the study?
Optimal management of oral anticoagulation after atrial fibrillation ablation remains uncertain.
Does oral anticoagulation discontinuation reduce bleeding without increasing thromboembolic events in patients with atrial fibrillation who remain arrhythmia-free 6 months after ablation?
Cohort (n=8,339)
Yes
Does oral anticoagulation discontinuation reduce bleeding without increasing thromboembolic events in patients with atrial fibrillation who remain arrhythmia-free 6 months after ablation?
Hazard Ratio: 0.93 (95% CI 0.67–1.29)
Absolute Event Rate: 4.01% vs 4.04%
Absolute Risk Reduction: 0.03%
Discontinuing oral anticoagulation 6 months after successful AF ablation in patients without prior thromboembolism appears safe and reduces non-major bleeding, though residual risk remains elevated in those with CHA2DS2-VA scores ≥4.
Should not yet alter post-ablation OAC decisions; leaves open need for RCTs to confirm safety in arrhythmia-free patients.
BACKGROUND AND AIMS: Optimal management of oral anticoagulation (OAC) after atrial fibrillation (AF) ablation remains uncertain. We evaluated thromboembolic and bleeding outcomes associated with OAC discontinuation versus continuation at a clinically relevant 6-month post-ablation landmark. METHODS: This target trial emulation used data from a multicentre prospective registry in China. Patients with CHA2DS2-VA scores ≥2, no prior thromboembolism, and no atrial arrhythmia recurrence within 6 months after ablation were classified according to OAC discontinuation or continuation at the 6-month landmark. The primary outcome was the composite of stroke, systemic embolism, and major bleeding. Inverse probability weighting was applied, with intention-to-treat as the primary analysis. RESULTS: Among 8,339 patients (mean age 68 years; 40.5% women), 4,406 discontinued and 3,933 continued OAC. The risk of the primary outcome did not differ significantly between groups (weighted HR 0.93; 95% CI 0.67-1.29). Thromboembolic risk was similarly comparable (HR 0.96; 95% CI 0.69-1.35). Clinically relevant non-major bleeding occurred less frequently after OAC discontinuation (HR 0.68; 95% CI 0.47-0.97). Findings were consistent in sensitivity analyses. Annualized thromboembolic rates after discontinuation were <1% in patients with CHA2DS2-VA scores 2-3 but 1.52% in those with scores ≥4. CONCLUSIONS: Among patients without prior thromboembolism who remained arrhythmia-free at 6 months after AF ablation, OAC discontinuation was not associated with a difference in the composite outcome of stroke, systemic embolism and major bleeding, compared with OAC continuation. Residual risk remained low in patients with CHA2DS2-VA scores 2-3 but exceeded conventional thresholds in those with scores ≥4.
No takes yet. Share an insight, caveat, or question.
Peng et al. (2026) conducted a cohort in Atrial fibrillation post-ablation (n=8,339). Oral anticoagulation discontinuation vs. Oral anticoagulation continuation was evaluated on Composite of stroke, systemic embolism, and major bleeding (HR 0.93, 95% CI 0.67-1.29). Oral anticoagulation discontinuation at 6 months post-ablation was not associated with a significant difference in the composite of stroke, systemic embolism, and major bleeding compared to continuation (HR 0.93).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: